Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many transitions between troublesome dyskinesia and OFF at endpoint vs baseline.

Gocovri is approved by the FDA for treating dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

The stock rose 4.63% to $5.20 in after-hours trading.

Obseva Says Nolasiban Progressing Toward Phase 3 Trial

Following its recent end-of-the Phase 2 meeting with the FDA, Obseva SA (NASDAQ: OBSV) said the regulatory body provided clarification on a number of key development issues for its oral oxytocin receptor antagonist nolasiban. The company said it anticipates beginning its U.S. Phase 3 clinical trial in the fourth quarter of 2019 or early 2020.

Based on the meeting, ObsEva said it anticipates working with FDA regarding certain issues, including timing of randomization and number of previous IVF failures, and expects to submit the IMPLANT 3 trial protocol with an updated IND in the third quarter of 2019.

Ironwood-Allergan's Irritable Bowel Syndrome Drug Aces Late-Stage Trial

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced positive topline results from a Phase 3b study evaluating Linzess 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation, or IBS-C.

"The trial met its primary multi-component endpoint and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adult IBS-C patients compared to placebo," the companies said.

The study also met the secondary endpoints.

Ironwood shares climbed 4.26% to $11.99 in after-hours trading.

Artcile come from: https://finance.yahoo.com/news/daily-biotech-pulse-positive-readouts-115149575.html

E-mail me when people leave their comments –

You need to be a member of The Brooklynne Networks to add comments!

Join The Brooklynne Networks

Brooklynne Brands & Services

Brands

TicketENVY- Find & Buy Sold out Concert, Sports and Theater Tickets Worldwide

SportsBrook- Fully Licensed Online Urban Sports Betting and Gaming Platform (Coming Soon)

KaratCity- Helping to provide regular people save and spend GOLD

VerticalRents- Helping Landlords mange and engage their Tenants Easier

MyTeleMedics- Get your Personal and Family Remote Healthcare Services NOW

FunderPass- Crowdfunding Platform for Urban Communty Projects Cause Activism and Upstanding Individual Needs

SeksCity Toys- Adult Pleasure Aids and Supplies (Must Be 18+)

Services

Brooklynne Info Weekly- News nd Events of featured Brooklyn Entrepreneurs and Community Related Issues

Brooklynne Style Daily- Brooklyn & NYC Based Style and Fashion News

Brooklynne Shop- Exclusive Graphic Designs from Featured Artists and Partners

Brooklynne TV- Watch Underground Indie Videos Podcasts & Live Events

Brooklynne Hookups-  Find Urban Dates and HookUps

Local Business Services

The Brooklynne Agency -Full Service Digital Marketing and Development Marketplace

Brooklynne Social - Free Social Media Marketing Mgmt Platform for Brands

The Brooklynne Agency - Office

Phetch.Co Ordering Mgmt

Xpurts by Phetch - Have REMOTE private conferences and meetings with Professional Experts

Go Phetch - Multi Cuisine Order and Delivery Mgmt Facilites and Marketplace for local Ethnic Food Providers in Brooklyn (Coming to NYC HOU DMV  & ATL)

Phetch IT- Order for Delivery Food Groceries Alcohol & Laundry from your favorite Independent merchants in your Area(Coming to NYC HOU DMV and ATL)

Phetch Charg- Start an Electric Vehicle Charging Station at yur Urban locations Tdday